Aslan out­li­cens­es atopic der­mati­tis an­ti­body in $138.5M deal

Aslan Phar­ma­ceu­ti­cals grant­ed ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights in Japan for an IL-13 an­ti­body to a Japan­ese drug­mak­er in a deal worth up to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER